279 related articles for article (PubMed ID: 31410224)
1. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy.
Zhang S; Zhou D; Zheng C; Xiong P; Zhu W; Zheng D
Mol Ther Oncolytics; 2021 Jun; 21():329-339. PubMed ID: 34141870
[TBL] [Abstract][Full Text] [Related]
3. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death.
Chen L; Qiu Y; Hao Z; Cai J; Zhang S; Liu Y; Zheng D
IUBMB Life; 2017 Sep; 69(9):735-744. PubMed ID: 28748573
[TBL] [Abstract][Full Text] [Related]
4. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
[TBL] [Abstract][Full Text] [Related]
5. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
[TBL] [Abstract][Full Text] [Related]
6. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
9. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
Brünker P; Wartha K; Friess T; Grau-Richards S; Waldhauer I; Koller CF; Weiser B; Majety M; Runza V; Niu H; Packman K; Feng N; Daouti S; Hosse RJ; Mössner E; Weber TG; Herting F; Scheuer W; Sade H; Shao C; Liu B; Wang P; Xu G; Vega-Harring S; Klein C; Bosslet K; Umaña P
Mol Cancer Ther; 2016 May; 15(5):946-57. PubMed ID: 27037412
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Importin β1 Augments the Anticancer Effect of Agonistic Anti-Death Receptor 5 Antibody in TRAIL-resistant Tumor Cells.
Kojima Y; Nishina T; Nakano H; Okumura K; Takeda K
Mol Cancer Ther; 2020 May; 19(5):1123-1133. PubMed ID: 32156787
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization.
Dubuisson A; Favreau C; Fourmaux E; Lareure S; Rodrigues-Saraiva R; Pellat-Deceunynck C; El Alaoui S; Micheau O
Cell Death Dis; 2019 Feb; 10(2):101. PubMed ID: 30718507
[TBL] [Abstract][Full Text] [Related]
13. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008.
Burvenich IJ; Lee FT; Cartwright GA; O'Keefe GJ; Makris D; Cao D; Gong S; Chueh AC; Mariadason JM; Brechbiel MW; Beckman RA; Fujiwara K; von Roemeling R; Scott AM
Clin Cancer Res; 2013 Nov; 19(21):5984-93. PubMed ID: 24045184
[TBL] [Abstract][Full Text] [Related]
15. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
16. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
[TBL] [Abstract][Full Text] [Related]
17. Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo.
Lei G; Xu M; Xu Z; Lu C; Tan S
Biomed Pharmacother; 2018 Feb; 98():271-279. PubMed ID: 29272788
[TBL] [Abstract][Full Text] [Related]
18. Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199.
Wang BT; Kothambawala T; Wang L; Matthew TJ; Calhoun SE; Saini AK; Kotturi MF; Hernandez G; Humke EW; Peterson MS; Sinclair AM; Keyt BA
Mol Cancer Ther; 2021 Dec; 20(12):2483-2494. PubMed ID: 34711645
[TBL] [Abstract][Full Text] [Related]
19. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]